Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid Dosage Forms
- 1.5k Downloads
To propose and test a new accelerated aging protocol for solid-state, small molecule pharmaceuticals which provides faster predictions for drug substance and drug product shelf-life.
Materials and Methods
The concept of an isoconversion paradigm, where times in different temperature and humidity-controlled stability chambers are set to provide a critical degradant level, is introduced for solid-state pharmaceuticals. Reliable estimates for temperature and relative humidity effects are handled using a humidity-corrected Arrhenius equation, where temperature and relative humidity are assumed to be orthogonal. Imprecision is incorporated into a Monte-Carlo simulation to propagate the variations inherent in the experiment. In early development phases, greater imprecision in predictions is tolerated to allow faster screening with reduced sampling. Early development data are then used to design appropriate test conditions for more reliable later stability estimations.
Examples are reported showing that predicted shelf-life values for lower temperatures and different relative humidities are consistent with the measured shelf-life values at those conditions.
The new protocols and analyses provide accurate and precise shelf-life estimations in a reduced time from current state of the art.
Key wordsaccelerated aging shelf-life stability
The authors would like to acknowledge the assistance of Dr. Julie Lorenz for her helpful discussions and suggestions. The authors would also like to acknowledge the assistance of Yan Liu, Shilpa Naik and Yukun Ren, each of whom contributed to the programming of the Monte-Carlo simulation.
- 3.B. Li, B. Andresen, M. F. Brown, R. A. Buzon, C. K.-F. Chiu, M. Couturier, E. Dias, F. J. Urban, V. J. Jasys, J. C. Kath, W. Kissel, T. Le, Z. J. Li, J. Negri, C. S. Poss, J. Tucker, D. Whritenour, and K. Zandi. Process development of CP-481715, a novel CCR1 antagonist. Org. Proc. Res. Dev. 9(4):466–471 (2005).CrossRefGoogle Scholar
- 4.D. T. Friesen, M. J. Gumkowski, R. J. Ketner, D. A. Lorenz, J. A. S. Nightingale, R. M. Shanker, and J. B. West. Pharmaceutical compositions of dispersions of drugs and neutral polymers. Int. Patent Appl. WO 2003000235A1 (2003) p. 210.Google Scholar
- 5.M. M Hayward. Preparation of [(2-piperazinyl-2-oxoethoxy)phenyl]alkanesulfonic acids and analogs as CCR1 receptor antagonists for treatment of inflammation and immune disorders. Int. Patent Appl. WO2002102787A2, p. 44 (2002).Google Scholar
- 6.M. F. Brown, A. S. Gaweco, R. P. Gladue, and M. M. Hayward. Preparation of piperazine sulfonic acid derivatives as chemokine receptors CCR1 antagonists for the treatment of fibrosis, Alzheimer disease and other disorders Int. Patent Appl. WO2004039377A1, p. 56 (2004).Google Scholar
- 7.U. Kaufmann. Preparation of piperazine derivatives as CCR1 antagonists for the treatment of endometriosis. Int. Patent Appl. WO2005079769A2 pp. 291 (2005).Google Scholar
- 8.K. M. Alsante, P. Boutros, M. A. Couturier, R. C. Friedmann, J. W. Harwood, G. J. Horan, A. J. Jensen, Q. Liu, L. L. Lohr, R. Morris, J. W. Raggon, G. L. Reid, D. P. Santafianos, T. R. Sharp, J. L. Tucker, and G. E. Wilcox. Pharmaceutical impurity identification: A case study using a multidisciplinary approach. J. Pharm.Sci. 93(9):2296–2309 (2004).PubMedCrossRefGoogle Scholar
- 11.S. Yoshioka and V. J. Stella. Stability of Drugs and Dosage Forms, Plenum, New York, 2000, pp. 108–113.Google Scholar
- 12.T. Hladon, B. Cwiertnia. The effect of humidity on the stability of diclofenac sodium in inclusion complex with ß-cyclodextrin in the solid state. Pharmazie 54(12):943–944 (1999).Google Scholar
- 14.M. Zajac. Stability of crystalline mecilliname sodium salt in the solid phase. Acta Pol. Pharm. 41:659–664 (1984).Google Scholar
- 17.Z. Plotkowiak. The effect of chemical character of certain penicillins on the stability of the ß-lactam group in their molecules. Pharmazie 44:837–839 (1989).Google Scholar